Zoetis Inc. (BVMF:Z1TS34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 152.90B -57.0% |
| Revenue (ttm) | 49.35B +1.6% |
| Net Income | 13.66B +1.8% |
| EPS | 31.75 +6.2% |
| Shares Out | n/a |
| PE Ratio | 11.19 |
| Forward PE | 11.32 |
| Dividend | 0.44 (1.79%) |
| Ex-Dividend Date | Jul 17, 2026 |
| Volume | 18,186 |
| Open | 23.70 |
| Previous Close | 23.70 |
| Day's Range | 23.70 - 24.94 |
| 52-Week Range | 23.00 - 53.75 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial numbers in USD Financial StatementsNews
Zoetis price target lowered to $85 from $99 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $85 from $99 and keeps an Overweight rating on the shares.
Zoetis price target lowered to $80 from $85 at UBS
UBS analyst Andrea Alfonso lowered the firm’s price target on Zoetis (ZTS) to $80 from $85 and keeps a Neutral rating on the shares.
Zoetis downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Zoetis (ZTS) to Market Perform from Outperform.
William Blair downgrades Zoetis, sees ‘too much uncertainty’
As previously reported, William Blair downgraded Zoetis (ZTS) to Market Perform from Outperform after Q2 results included worse-than-expected derm declines, continued Trio share loss, and continued de...
Zoetis Earnings Call Transcript: Q2 2026
Q2 saw flat revenue and a 2% decline in adjusted net income, with U.S. companion animal under pressure from declining clinic visits and heightened competition, while international and livestock segments grew. Full-year guidance was lowered, reflecting persistent headwinds and increased promotional activity.
Zoetis Slides: Q2 2026
Zoetis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Zoetis Earnings release: Q2 2026
Zoetis released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Zoetis Quarterly report: Q2 2026
Zoetis has published its Q2 2026 quarterly earnings report on August 6, 2026.
Zoetis cuts annual forecasts as pet healthcare demand slows
Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and increased competiti...
Zoetis appoints Jay Saccaro as CFO, COO
Zoetis (ZTS) announced the appointment of James Saccaro as Executive Vice President, CFO and COO, effective August 17. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance…
Zoetis reports Q2 adjusted EPS $1.87, consensus $1.85
Reports revenue $2.5B, consensus $2.51B. “Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts ...
Zoetis sees FY26 adjusted EPS $6.15-$6.25, consensus $6.87
Sees revenue $9.12B-$9.32B, consensus $9.74B.
Zoetis Announces Second Quarter 2026 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026. The co...
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effe...
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 3,517 puts trading, or 3x expected. Most active are Aug-26 60 puts and Aug-26 70 puts, with total volume in those strikes near…
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 3,800 puts trading, or 5x expected. Most active are Aug-26 70 puts and Aug-26 75 puts, with total volume in those strikes near…
Zoetis price target lowered to $85 from $99 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $85 from $99 and keeps a Neutral rating on the shares.
Zoetis price target lowered to $99 from $115 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $99 from $115 and keeps an Overweight rating on the shares. U.S. vet practices are growing revenue by raising…
Zoetis launches Portela in Canada, the EU
Zoetis (ZTS) announced the commercial launch of Portela in Canada and the European Union member states. Portela is the first long-acting anti-nerve growth factor monoclonal antibody therapy for cats, ...
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. P...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS
Wall Street's Reassessment of Zoetis Accelerated as Analyst Downgrades Followed Each Corrective Disclosure, Reflecting Growing Skepticism That Management's Companion Animal Growth Narrative Was Built ...
Zoetis announces it recently launched Lenivia in Canada, EU
Zoetis (ZTS) announced that it has recently launched Lenivia in Canada and the European Union, EU, member states – a new long-acting monoclonal antibody therapy designed to deliver up to…
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) m...
Zoetis enters agreement to acquire VitalRADS, terms not disclosed
Zoetis (ZTS) announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisiti...
Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with...